{"name":"Reviva Pharmaceuticals","slug":"reviva-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":22907368,"netIncome":-29918802,"cash":15503088,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOR1hxdTlDMHhuQkd2TzhYaEhkZk8tdFhhT19UVjJmWmxCWV85RElmR1RXUW9ZTEJ1TzQ5YXVjMFRDaXk0M2h6RzNKeV9ZTElxek5WYjFNRWEtTEdJUkVzQmpMRFVRamd3SHVRTnhVTWhuWUtHdElja2g0Mk5tSFJkMFktM3lVcVQ2OFZYVlg3NWwxSWRJMXdaMVFKakkyVjdIal9BSEpIUnZlSFFUeF9mMzBZZFRqRGts?oc=5","date":"2026-03-04","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Wednesday's Pre-Market Session - 20/20 Biolabs (NASDAQ:AIDX), Can Fite Bi - Benzinga","headline":"12 Health Care Stocks Moving In Wednesday's Pre-Market Session - 20/20 Biolabs (NASDAQ:AIDX), Can Fite Bi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPUURJY280ZkQ0SkVIeVpKb3ByazhMdU1tMkVQQ2I3QjZEYzRBaUl0LWlJcVkwcF9pTE02RF9uZDlhc2hadkVWWkZHZHFYa2t2cGp2elVPRXRXbFRhcHhkX0pyLXVTeWVoajFUa1VTckJ6b2JiMzUxOFRFZmtPbjhISy1fdnlxMmR3YWtrLUx4WUdKTXk3aFoyVDZqNXZ0cFpFNEs2T0U1VEFkYldHYVhsNjBTa3UzcEJweDhRUQ?oc=5","date":"2026-01-23","type":"pipeline","source":"TipRanks","summary":"Reviva Pharmaceuticals Granted Nasdaq Extension to Regain Compliance - TipRanks","headline":"Reviva Pharmaceuticals Granted Nasdaq Extension to Regain Compliance","sentiment":"neutral"},{"date":"2026-01-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNZE81ektuTmhZTzJWZUZIT2hvWFItOWZrb2dFUEtWVE1EVWo3RVVha2VNY3hKWHpCNUp5QkZONUdnbzRXdEFnLVctcnNNYnktWFhBSGtTQ0pIQS15aEtXdjNRVVhISjc3TTllaUFUTFdPYm11aDJGZlFRWEhVcEFKRVdTV3JrR2dRYnV5cUJTRVRmWDc4?oc=5","date":"2026-01-11","type":"pipeline","source":"Yahoo Finance","summary":"Reviva Pharmaceuticals Holdings (RVPH) Records 37% Gain So far in 2026 - Yahoo Finance","headline":"Reviva Pharmaceuticals Holdings (RVPH) Records 37% Gain So far in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOemxObDU4MERNR0dMRXg1d2VzZ2VBWXNMNVJmek50MGh4QlQ2ODlHTjljdFI4NVVWdXhEZzJTVXlJQ0dNQXVra0NTRTREUjRpTTRxYThkY1ZEWjdocWJrQ21uMzQ5YnFWdGVUQWppNlpCNEFvWENaeG45YUJWRHd6UXJBMkN4a2cxZlJWRGRzWnlUZ3kyV1FyVE5Sbmp0V3ZOWkFfQ3lra2FqSWQ2ZVhrS05GQmlSb2tRaXc?oc=5","date":"2025-12-23","type":"regulatory","source":"Stock Titan","summary":"FDA recommends another large trial for new schizophrenia drug - Stock Titan","headline":"FDA recommends another large trial for new schizophrenia drug","sentiment":"neutral"},{"date":"2025-12-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQVWNRckhxN1o3U3h3RThhejRSSlFOZkRvMTRKd0Fua0V1T1B6Mjg5UzdGcWIzMlZoUlA1RnFSQlItdzRoeU1XSXZhemk4N2VIQXFKMW5yM3hnLW5JM2k2WlljM00tLVVQVjg2UXBjcnV1NkhfOW1HbWVweTktb3l0VGJHT3ZYMi04UC1xdDNFRTlQYUt5MFhwYlpkcEJNeWJFQmJoZVUwbmhlRGxJcXQ3UGF4N01lcVIyOXZ6NUZR?oc=5","date":"2025-12-16","type":"pipeline","source":"Seeking Alpha","summary":"Reviva Pharmaceuticals: Brilaroxazine Seems Efficacious, But Progress Is Slow And Dilution Is High - Seeking Alpha","headline":"Reviva Pharmaceuticals: Brilaroxazine Seems Efficacious, But Progress Is Slow And Dilution Is High","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPYklUTU1MT2lJaVdoVG8xbUhNVzBPTmh5eVlBa19pT25aWVJnb3dqZ2R2YmU3a3AxVHAzYXBhLXluTVQ3WDJockItbUdFel9zYWI0NGdieWV6RS10TXBKQWJuWnNjMndCQ1Ztd2JvM2NpMU9RYVZZNUU5UGl4a3VsdmUybDkzQi1yYVRzV0ZxVDB3dVRQX2RIY0U3YTlRLW1h?oc=5","date":"2025-12-01","type":"pipeline","source":"RTTNews","summary":"Is RVPH Positioned For NDA Submission In Schizophrenia By 2026? - RTTNews","headline":"Is RVPH Positioned For NDA Submission In Schizophrenia By 2026?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFBiTE1ic2wyaExSY2RlWXoyS3BPYXBUT0RGRmI1VmRwZ3JKR3BRa2praHZFWUltV3lYWHBpMUp3WWdla2JqdndvRG1JX1ZSY3pyRHhJYkRTY0lOM2I5?oc=5","date":"2025-11-29","type":"pipeline","source":"Finimize","summary":"Reviva’s Schizophrenia Bet Pits Huge Upside Against Harsh Risks - Finimize","headline":"Reviva’s Schizophrenia Bet Pits Huge Upside Against Harsh Risks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPWmdfTmRLbGx5bFBKV1QtOTBXMGxDdTZRRTBGd2RGWHdzYXJxbXR6dU41SVpiTVA5QzhlbFdpN0hiRjhQTFprMXlGWFZiMnBoZGo3RFItNFo2Zk9IS2VYZDlTRi1NLTc1VWtWelBmT1dQMURqUm9ZbnhVVkpaeWRXa2JlUUZ2RG15M0ZjX2QxbHNxc1pta3M4X2tIN2hzOW1ZQVc0RlVLRTFSNkQwY0lTWElweFQ3cURJWE9SYlRxQ0NWVHdRVl9reVpn?oc=5","date":"2025-10-09","type":"pipeline","source":"MarketBeat","summary":"Weiss Ratings Reiterates Sell (E+) Rating for Reviva Pharmaceuticals (NASDAQ:RVPH) - MarketBeat","headline":"Weiss Ratings Reiterates Sell (E+) Rating for Reviva Pharmaceuticals (NASDAQ:RVPH)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOME5sdHdWZFUtQXJfZTBtMUJyVmtOSnN1X1NLVXZRVlRnbEQ5amo2TktpTVRKMlFpSHdyQ0FSQTNuY081YVFEc0NpdU14S3Q2dV9lM2tsVHFfR29RRVF4X1lTbFZIVWxCWUdzVk15T0JYMEhseDZLQ0F5UV9CMFlWN3FBSVFRbWJYUENvU0Z5OXUyYkJwTjV0TWU5cUNaRzQtSl8tNmN2aTBvWFduODlF?oc=5","date":"2025-10-02","type":"pipeline","source":"Stock Titan","summary":"Small-Cap CNS Drug Developer Reviva Takes Stage at Roth Conference to Discuss Blockbuster Potential - Stock Titan","headline":"Small-Cap CNS Drug Developer Reviva Takes Stage at Roth Conference to Discuss Blockbuster Potential","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":22907368,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-29918802,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":15503088,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}